Vincenzo Callea

Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti et autres

Abstract Purpose: Chromosome 13q14 deletion occurs in a substantial number of chronic lymphocytic leukemia (CLL) patients and it is believed to play a pathogenetic role. The exact mechanisms involved in this lesion have not yet been fully elucidated because of its heterogeneity …

it (code pays fourni par la source)

Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti et autres

Abstract Purpose: Chromosome 13q14 deletion occurs in a substantial number of chronic lymphocytic leukemia (CLL) patients and it is believed to play a pathogenetic role. The exact mechanisms involved in this lesion have not yet been fully elucidated because of its heterogeneity …

Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti et autres

Supplementary Figures S1-S2 and Supplementary Tables S1-S5.

Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti et autres

Supplementary Figures S1-S2 and Supplementary Tables S1-S5.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna et autres

BACKGROUND: Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines …

it, il (code pays fourni par la source)

Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial

Carolina Terragna, Angela Flores Dico, Marina Martello, Vincenzo Callea et autres

Abstract Background. Array-based technology has been showing a great impact on clinical cancer cytogenetic, especially on genetically heterogeneous disease, such as MM, where relevant lesions might be the hallmarks of different patients’ subgroups, thus becoming of clinical relevance as well. We present …

it, no, nl (code pays fourni par la source)

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Simone Ferrero, Marco Ladetto, Daniela Drandi, Federica Cavallo et autres

it (code pays fourni par la source)

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Alberto Rocci, Craig C. Hofmeister, Susan M. Geyer, Andrew Stiff et autres

it, us, ch (code pays fourni par la source)

Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients

Robin Foà, Ilaria Del Giudice, Antonio Cuneo, Giovanni Del Poeta et autres

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and …

it (code pays fourni par la source)

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Simone Ferrero, Marco Ladetto, Daniela Drandi, Federica Cavallo et autres

Abstract Background and aims The extensive use of new drugs in multiple myeloma (MM) allowed the achievement of unprecedented levels of cytoreduction and major advantages in survival rates, though almost all patients still relapse after a successful treatment. PCR-based minimal residual disease …

it (code pays fourni par la source)

Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma

Flavia Pichiorri, Alberto Rocci, Craig C. Hofmeister, Susan M. Geyer et autres

Abstract Purpose While international stage (ISS) and the presence of absence of cytogenetic abnormalities on FISH somewhat define the clinical risk of MM patients, additional biomarkers are necessary for more precise risk-based classification. Emerging studies have shown that circulating microRNAs (miRNAs) can …

us, it (code pays fourni par la source)

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

Sara Bringhen, María‐Victoria Mateos, Sonja Zweegman, Alessandra Larocca et autres

Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatment-related side effects are frequent and full drug doses difficult to tolerate. We retrospectively analyzed data from 1435 elderly patients enrolled in 4 European phase III trials including …

it, es, nl (code pays fourni par la source)